Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.49 |
| ▸ | PAM | P19021 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10086062 | 1.00 | ALOX5 (0.58) | ALOX5DGKALPAR1LPAR3PAM | |
| SCHEMBL19633081 | 0.95 | ALOX5 (0.54) | ALOX5DGKALPAR1LPAR3PAM | |
| SCHEMBL29255772 | 0.94 | ALOX5 (0.58) | ALOX5DGKALPAR1LPAR3PAM | |
| SCHEMBL18356005 | 0.90 | ALOX5 (0.49) | ALOX5DGKALPAR1LPAR3PAM | |
| SCHEMBL19633080 | 0.90 | TBXA2R (0.49) | ALOX5DGKALPAR1LPAR3MAPT | |
| SCHEMBL10081244 | 0.90 | ALOX5 (0.49) | ALOX5DGKALPAR1LPAR3PAM | |
| SCHEMBL18995461 | 0.90 | ALOX5 (0.49) | ALOX5DGKALPAR1LPAR3PAM | |
| SCHEMBL10084982 | 0.89 | ALOX5 (0.60) | ALOX5DGKAPAMTSHRMAPT | |
| SCHEMBL11045151 | 0.89 | ALOX5 (0.60) | ALOX5DGKAPAMTSHRMAPT | |
| SCHEMBL11045153 | 0.89 | ALOX5 (0.60) | ALOX5DGKAPAMTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9687448-B2 | Nucleic acid lipid particle formulations | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9682922-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2575764-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2016-01-14 | — | — | US | disclosed |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | BANK OF AMERICA, N.A. | 2015-10-29 | — | — | US | disclosed |
| US-9012498-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | ALOX5 145/4885DGKA 336/4885LPAR1 70/4885 |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | NPC1L1, NPC1, CETP | ALOX5 1451/4885DGKA 394/4885LPAR1 110/4885 |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, ABHD16A, CETP | ALOX5 369/4885DGKA 373/4885LPAR1 20/4885 |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, NPC1L1, CETP | ALOX5 477/4885DGKA 423/4885LPAR1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.